January 29, 2026
Sandoz and Teva have won a reprieve from a former pharmaceutical marketing executive claiming the drugmakers and their officers offered him up to federal prosecutors with fabricated assertions of price-fixing, with a New York federal judge concluding the suit "does not come close" to the standard for malicious prosecution.